Immutep Limited(IMMP)Earnings, Financials & Key Ratios
IMMP•NASDAQ
Price updated Jun 19, 2026
AboutImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.Show more
- Revenue$5M+31.3%
- EBITDA-$124M-44.4%
- Net Income-$61M-43.8%
- EPS (Diluted)-0.42-16.7%
- Gross Margin-1117.55%-13.9%
- EBITDA Margin-2464.17%-10.0%
- Operating Margin-2506.49%-9.3%
- Net Margin-1218.02%-9.5%
- ROE-36.88%-40.7%
IMMP Key Insights
Immutep Limited (IMMP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Sales declining 7.6% over 5 years
- ✗Shares diluted 21.2% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMMP Price & Volume
Immutep Limited (IMMP) stock price & volume — 10-year historical chart
Loading chart...
IMMP Growth Metrics
Immutep Limited (IMMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.19%
5 Years-7.59%
3 Years209.35%
TTM54.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-44.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.7%
Return on Capital
10 Years-61.88%
5 Years-57.55%
3 Years-65.19%
Last Year-75.4%
IMMP Recent Earnings
Immutep Limited (IMMP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (70%)●Beat Revenue 4/12 qtrs (40%)
Q1 2026Latest
Feb 24, 2026Metric
Actual
Est
EPS
$0.15-9.0%
$0.14
Rev
$4M-42.0%
$7M
Q3 2025
Aug 28, 2025Metric
Actual
Est
EPS
$0.18-44.0%
$0.12
Rev
$1M
—
Q1 2025
Feb 26, 2025Metric
Actual
Est
EPS
$0.01+88.7%
$0.08
Rev
$2M+349.7%
$433,237
Q3 2024
Aug 30, 2024Metric
Actual
Est
EPS
$0.01+86.1%
$0.08
Rev
$1M-6.6%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.15vs $0.14-9.0% | $4Mvs $7M-42.0% |
| Q3 2025 | Aug 28, 2025 | $0.18vs $0.12-44.0% | $1M |
| Q1 2025 | Feb 26, 2025 | $0.01vs $0.08+88.7% | $2Mvs $433,237+349.7% |
| Q3 2024 | Aug 30, 2024 | $0.01vs $0.08+86.1% | $1Mvs $1M-6.6% |
Based on last 12 quarters of dataView full earnings history →
IMMP Peer Comparison
Immutep Limited (IMMP) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTX | 204.62M | 2.86 | -2.03 | -30.9% | 0.24 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 FHTX | 243.66M | 4.15 | -3.52 | 36.75% | -266.88% | |||
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare IMMP vs Peers
Immutep Limited (IMMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMMP Income Statement
Immutep Limited (IMMP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.22M | 2.63M | 139.78K | 7.49M | 3.86M | 170.37K | 3.51M | 3.84M | 5.04M |
Revenue Growth % | 2311.59% | -37.69% | -94.69% | 5255.8% | -48.4% | -95.59% | 1957.72% | 9.59% | 31.28% |
Cost of Goods Sold | 1.7M | 9.99M | 16.59M | 22.47M | 17.24M | 2.06M | 2.06M | 41.55M | 61.41M |
COGS % of Revenue | 40.31% | 379.77% | 11869.34% | 300.18% | 446.22% | 1211.18% | 58.81% | 1081.42% | 1217.55% |
Gross Profit | 2.52M▲ 0% | -7.36M▼ 392.0% | -16.45M▼ 123.5% | -14.99M▲ 8.9% | -13.37M▲ 10.8% | -1.89M▲ 85.8% | 1.44M▲ 176.3% | -37.7M▼ 2711.3% | -56.37M▼ 49.5% |
Gross Margin % | 59.69% | -279.77% | -11769.34% | -200.18% | -346.22% | -1111.18% | 41.19% | -981.42% | -1117.55% |
Gross Profit Growth % | 136.6% | -392.05% | -123.54% | 8.91% | 10.76% | 85.84% | 176.27% | -2711.31% | -49.49% |
Operating Expenses | 9.46M | 14.82M | 19.1M | 22.56M | 18.3M | 32.55M | 44.94M | 50.4M | 70.06M |
OpEx % of Revenue | 224.03% | 563.31% | 13665.71% | 301.32% | 473.82% | 19104.22% | 1281.82% | 1311.84% | 1388.94% |
Selling, General & Admin | 4.35M | 7.24M | 6.13M | 6.34M | 6.28M | 7.21M | 14.08M | 8.85M | 8.64M |
SG&A % of Revenue | 102.97% | 275.31% | 4384.88% | 84.63% | 162.63% | 4232.06% | 401.68% | 230.42% | 171.39% |
Research & Development | 7.53M | 9.99M | 16.59M | 20.4M | 17.24M | 31.34M | 28.79M | 41.55M | 61.41M |
R&D % of Revenue | 178.27% | 379.77% | 11869.34% | 272.44% | 446.22% | 18396.29% | 821.33% | 1081.42% | 1217.55% |
Other Operating Expenses | -751.82K | -866.85K | -3.62M | -4.17M | -5.22M | -6M | 2.06M | 0 | 0 |
Operating Income | -9.35M▲ 0% | -11.69M▼ 25.0% | -20.42M▼ 74.6% | -16.02M▲ 21.5% | -31.68M▼ 97.7% | -33.94M▼ 7.1% | -77.69M▼ 128.9% | -88.1M▼ 13.4% | -126.42M▼ 43.5% |
Operating Margin % | -221.55% | -444.55% | -14606.55% | -213.97% | -820.05% | -19920.03% | -2216.05% | -2293.26% | -2506.49% |
Operating Income Growth % | 84.79% | -25.03% | -74.6% | 21.54% | -97.75% | -7.14% | -128.92% | -13.41% | -43.49% |
EBITDA | -7.65M | -9.88M | -18.54M | -13.94M | -29.79M | -32.1M | -75.83M | -86.09M | -124.29M |
EBITDA Margin % | -181.24% | -375.78% | -13262.21% | -186.19% | -771.15% | -18840.57% | -2163.01% | -2240.86% | -2464.17% |
EBITDA Growth % | 87.14% | -29.19% | -87.54% | 24.81% | -113.7% | -7.76% | -136.24% | -13.53% | -44.37% |
D&A (Non-Cash Add-back) | 1.7M | 1.81M | 1.88M | 2.08M | 1.89M | 1.84M | 1.86M | 2.01M | 2.13M |
EBIT | -9.46M | -12.74M | -18.34M | -13.46M | -19.66M | -33.84M | -41.43M | -46.56M | -65.01M |
Net Interest Income | 0 | 177.19K | 397.28K | 189.08K | 95.5K | 132.09K | 918.6K | 3.85M | 5.25M |
Interest Income | 104.37K | 177.19K | 397.28K | 199.54K | 105.33K | 224.52K | 939K | 3.88M | 5.25M |
Interest Expense | 0 | 0 | 0 | 10.46K | 9.82K | 92.43K | 20.4K | 30.59K | 0 |
Other Income/Expense | 4.64M | 6.61M | 2.07M | 2.55M | 1.77M | 1.63M | 37.79M | 45.39M | 64.99M |
Pretax Income | -10.1M▲ 0% | -12.74M▼ 26.1% | -18.34M▼ 43.9% | -13.47M▲ 26.6% | -29.9M▼ 122.0% | -32.21M▼ 7.7% | -39.9M▼ 23.9% | -42.72M▼ 7.1% | -61.43M▼ 43.8% |
Pretax Margin % | -239.36% | -484.49% | -13123.28% | -179.9% | -774.12% | -18906.49% | -1138.04% | -1111.87% | -1218.02% |
Income Tax | -737.39K | 1.68K | -2.07M | 37 | 33 | 34 | 0 | 0 | 0 |
Effective Tax Rate % | 7.3% | -0.01% | 11.3% | -0% | -0% | -0% | 0% | 0% | 0% |
Net Income | -9.37M▲ 0% | -12.75M▼ 36.1% | -16.27M▼ 27.7% | -13.47M▲ 17.2% | -29.9M▼ 122.0% | -32.21M▼ 7.7% | -39.9M▼ 23.9% | -42.72M▼ 7.1% | -61.43M▼ 43.8% |
Net Margin % | -221.89% | -484.55% | -11640.01% | -179.9% | -774.12% | -18906.51% | -1138.04% | -1111.87% | -1218.02% |
Net Income Growth % | 84.9% | -36.07% | -27.65% | 17.22% | -122.02% | -7.72% | -23.86% | -7.07% | -43.82% |
Net Income (Continuing) | -9.37M | -12.75M | -18.34M | -13.47M | -29.9M | -32.21M | -39.9M | -42.72M | -61.43M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.44▲ 0% | -0.48▼ 9.1% | -0.47▲ 2.1% | -0.33▲ 29.8% | -0.49▼ 48.5% | -0.37▲ 24.5% | -0.44▼ 18.9% | -0.36▲ 18.2% | -0.42▼ 16.7% |
EPS Growth % | 83.7% | -9.09% | 2.08% | 29.79% | -48.48% | 24.49% | -18.92% | 18.18% | -16.67% |
EPS (Basic) | -0.44 | -0.48 | -0.47 | -0.33 | -0.49 | -0.37 | -0.44 | -0.36 | -0.42 |
Diluted Shares Outstanding | 42.69M | 42.69M | 42.69M | 40.73M | 60.43M | 86.23M | 90.06M | 120.11M | 145.58M |
Basic Shares Outstanding | 42.69M | 42.69M | 42.69M | 40.73M | 60.43M | 86.23M | 90.06M | 119.99M | 145.58M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMMP Balance Sheet
Immutep Limited (IMMP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.92M | 28.64M | 23.54M | 31.15M | 68.42M | 90.81M | 134.97M | 191.35M | 149.1M |
Cash & Short-Term Investments | 12.24M | 23.48M | 16.57M | 26.32M | 60.13M | 80M | 123.42M | 181.88M | 129.69M |
Cash Only | 12.24M | 23.48M | 16.57M | 26.32M | 60.13M | 80M | 123.42M | 161.79M | 67.41M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.09M | 62.28M |
Accounts Receivable | 2.19M | 3.48M | 5.23M | 3.39M | 6.12M | 8.37M | 7.97M | 7.56M | 7.46K |
Days Sales Outstanding | 189.71 | 483.19 | 13.66K | 165.36 | 578.68 | 17.94K | 830.13 | 718.1 | 0.54 |
Inventory | 642K | 0 | 0 | 0 | -5.66M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 137.71 | - | - | - | - | - | - | - | - |
Other Current Assets | 3.08M | 0 | 0 | 0 | 6.16M | 0 | 0 | 0 | 10.87M |
Total Non-Current Assets | 19.04M | 18.36M | 17M | 15.45M | 13.61M | 11.36M | 12.48M | 10.23M | 7.89M |
Property, Plant & Equipment | 24.2K | 26.45K | 52.95K | 250.57K | 309.7K | 308.08K | 468.51K | 679.72K | 569.48K |
Fixed Asset Turnover | 174.43x | 99.45x | 2.64x | 29.88x | 12.47x | 0.55x | 7.48x | 5.65x | 8.86x |
Goodwill | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K |
Intangible Assets | 18.91M | 18.22M | 16.84M | 15.08M | 12.74M | 10.44M | 9.38M | 8.13M | 7.09M |
Long-Term Investments | 16.21M | 15.62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -19.04M | -18.36M | -17M | 0 | 454.19K | 495.66K | 2.52M | 1.31M | 116.64K |
Total Assets | 34.96M▲ 0% | 47M▲ 34.4% | 40.54M▼ 13.7% | 46.6M▲ 14.9% | 82.03M▲ 76.0% | 102.17M▲ 24.6% | 147.45M▲ 44.3% | 201.58M▲ 36.7% | 156.98M▼ 22.1% |
Asset Turnover | 0.12x | 0.06x | 0.00x | 0.16x | 0.05x | 0.00x | 0.02x | 0.02x | 0.03x |
Asset Growth % | -17.84% | 34.42% | -13.74% | 14.94% | 76.04% | 24.55% | 44.32% | 36.71% | -22.12% |
Total Current Liabilities | 2.63M | 3.85M | 5.3M | 3.36M | 5.34M | 6.41M | 9.77M | 10.49M | 12.76M |
Accounts Payable | 1.14M | 1.62M | 2.56M | 1.64M | 1.82M | 2.87M | 5.45M | 3.79M | 5.53M |
Days Payables Outstanding | 244.26 | 59.02 | 56.26 | 26.63 | 38.64 | 506.98 | 964.49 | 33.3 | 32.89 |
Short-Term Debt | 0 | 0 | 0 | 0 | 208.19K | 0 | 0 | 0 | 1.1M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.45M | 2.05M | 2.5M | 1.29M | 2.75M | 3.02M | 354.84K | 428.71K | 446.95K |
Current Ratio | 6.05x | 7.43x | 4.44x | 9.26x | 12.81x | 14.16x | 13.81x | 18.25x | 11.69x |
Quick Ratio | 5.80x | 7.43x | 4.44x | 9.26x | 13.87x | 14.16x | 13.81x | 18.25x | 11.69x |
Cash Conversion Cycle | 83.15 | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 5.8M | 9.62M | 10.85M | 9.93M | 3.42M | 1.68M | 1.21M | 1.57M | 589.23K |
Long-Term Debt | 5.78M | 6.65M | 7.64M | 8.79M | 2.53M | 1.45M | 835.45K | 960.76K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 132.97K | 80.11K | 107.49K | 207.62K | 399.41K | 314.91K |
Deferred Tax Liabilities | 2.84M | 2.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20.5K | 2.98M | 3.21M | 1.01M | 811.88K | 117.25K | 164.43K | 211.01K | 274.31K |
Total Liabilities | 8.43M | 13.48M | 16.15M | 13.3M | 8.76M | 8.09M | 10.98M | 12.06M | 13.35M |
Total Debt | 5.78M | 6.65M | 7.64M | 9.05M | 2.82M | 1.73M | 1.23M | 1.59M | 1.63M |
Net Debt | -6.46M | -16.83M | -8.93M | -17.27M | -57.31M | -78.26M | -122.19M | -160.2M | -65.78M |
Debt / Equity | 0.22x | 0.20x | 0.31x | 0.27x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | - | - | - | -1531.88x | -3224.10x | -367.17x | -3808.07x | -2879.79x | - |
Total Equity | 26.53M▲ 0% | 33.52M▲ 26.3% | 24.39M▼ 27.2% | 33.3M▲ 36.5% | 73.27M▲ 120.0% | 94.08M▲ 28.4% | 136.47M▲ 45.1% | 189.52M▲ 38.9% | 143.64M▼ 24.2% |
Equity Growth % | -24.87% | 26.34% | -27.25% | 36.54% | 120.04% | 28.4% | 45.06% | 38.87% | -24.21% |
Book Value per Share | 0.62 | 0.79 | 0.57 | 0.82 | 1.21 | 1.09 | 1.52 | 1.58 | 0.99 |
Total Shareholders' Equity | 26.53M | 33.52M | 24.39M | 33.3M | 73.27M | 94.08M | 136.47M | 189.52M | 143.64M |
Common Stock | 195.35M | 213.23M | 221.09M | 242.99M | 313.42M | 367.41M | 446.27M | 542.11M | 535.07M |
Retained Earnings | -231.84M | -244.58M | -262.24M | -275.71M | -274.64M | -302.34M | -339.93M | -382.65M | -444.08M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 63.02M | 64.87M | 65.53M | 66.01M | 34.49M | 29M | 30.13M | 30.06M | 52.65M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMMP Cash Flow Statement
Immutep Limited (IMMP) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.51M | -7.78M | -15.29M | -10.84M | -17.64M | -30.23M | -35.88M | -34.82M | -62.05M |
Operating CF Margin % | -201.51% | -295.64% | -10935.88% | -144.79% | -456.67% | -17743.69% | -1023.56% | -906.36% | -1230.22% |
Operating CF Growth % | 24.78% | 8.58% | -96.57% | 29.09% | -62.74% | -71.37% | -18.7% | 2.96% | -78.2% |
Net Income | -9.37M | -12.75M | -18.34M | -13.47M | -29.9M | -32.21M | -39.9M | -42.72M | -61.43M |
Depreciation & Amortization | 1.7M | 1.81M | 1.88M | 2.08M | 2.07M | 2.06M | 2.06M | 2.26M | 2.39M |
Stock-Based Compensation | 862.23K | 2.26M | 1.58M | 1.72M | 1.7M | 1.49M | 2M | 1.8M | 1.16M |
Deferred Taxes | -218.57K | -9.79M | -5.71M | -6.11M | -7.29M | 0 | -4.99M | 0 | 0 |
Other Non-Cash Items | 751.82K | 10.94M | 5.65M | 4.84M | 17.77M | -8.04K | 4.17M | 379.87K | 4.37M |
Working Capital Changes | -2.24M | -252.22K | -345.19K | 94.16K | -1.99M | -1.56M | 764.6K | 3.46M | -8.54M |
Change in Receivables | -2.03M | -1.24M | -1.76M | 1.9M | -2.83M | -2.25M | -1.61M | 601.76K | -2.52M |
Change in Inventory | 648.58K | 0 | 0 | 0 | 0 | 813.92K | 0 | 0 | 0 |
Change in Payables | 1.38M | 1.08M | 1.4M | -2.13M | 1.38M | 1.44M | 3.27M | 0 | 0 |
Cash from Investing | -6.64K | -11.89K | -41.43K | -19.35K | -15.6K | -22.91K | -31K | -21.02M | -38.53M |
Capital Expenditures | -6.64K | -11.89K | -41.43K | -19.35K | -15.6K | -22.91K | -47K | -932.37K | -45.77K |
CapEx % of Revenue | 0.16% | 0.45% | 29.64% | 0.26% | 0.4% | 13.45% | 1.34% | 24.27% | 0.91% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -6.64K | -11.89K | -41.43K | 0 | 0 | 0 | 16K | 0 | -38.49M |
Cash from Financing | -8.53K | 18.4M | 8.01M | 20.48M | 52.68M | 50.33M | 76.04M | 95.18M | -525.12K |
Debt Issued (Net) | 0 | 0 | 0 | -77.54K | -214.38K | -222.54K | -211.97K | -226.49K | -270.67K |
Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -8.53K | 1.44M | 3.14M | -1.47M | 9.59M | -2.43M | -3.83M | -4.83M | -254.46K |
Net Change in Cash | -8.64M▲ 0% | 11.24M▲ 230.0% | -6.91M▼ 161.5% | 9.75M▲ 241.2% | 34.27M▲ 251.4% | 19.4M▼ 43.4% | 43.42M▲ 123.8% | 38.37M▼ 11.6% | -94.38M▼ 346.0% |
Free Cash Flow | -8.51M▲ 0% | -7.79M▲ 8.5% | -15.33M▼ 96.8% | -10.86M▲ 29.2% | -17.66M▼ 62.6% | -30.25M▼ 71.3% | -35.93M▼ 18.8% | -35.75M▲ 0.5% | -62.1M▼ 73.7% |
FCF Margin % | -201.67% | -296.09% | -10965.53% | -145.04% | -457.08% | -17757.14% | -1024.9% | -930.63% | -1231.13% |
FCF Growth % | 24.9% | 8.51% | -96.8% | 29.16% | -62.6% | -71.35% | -18.77% | 0.49% | -73.68% |
FCF per Share | -0.20 | -0.18 | -0.36 | -0.27 | -0.29 | -0.35 | -0.40 | -0.30 | -0.43 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.61x | 0.94x | 0.80x | 0.59x | 0.94x | 0.90x | 0.82x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35.55K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMMP Key Ratios
Immutep Limited (IMMP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -206.69% | -30.29% | -42.45% | -56.19% | -46.69% | -56.12% | -38.5% | -34.61% | -26.21% | -36.88% |
Return on Invested Capital (ROIC) | -237.03% | -35.48% | -47.71% | -95.25% | -76.3% | -148.54% | -160.21% | -387.2% | -303.07% | -176.93% |
Gross Margin | -3932.82% | 59.69% | -279.77% | -11769.34% | -200.18% | -346.22% | -1111.18% | 41.19% | -981.42% | -1117.55% |
Net Margin | -35426.72% | -221.89% | -484.55% | -11640.01% | -179.9% | -774.12% | -18906.51% | -1138.04% | -1111.87% | -1218.02% |
Debt / Equity | 0.14x | 0.22x | 0.20x | 0.31x | 0.27x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x |
Interest Coverage | -7497.79x | - | - | - | -1531.88x | -3224.10x | -367.17x | -3808.07x | -2879.79x | - |
FCF Conversion | 0.18x | 0.91x | 0.61x | 0.94x | 0.80x | 0.59x | 0.94x | 0.90x | 0.82x | 1.01x |
Revenue Growth | -91.64% | 2311.59% | -37.69% | -94.69% | 5255.8% | -48.4% | -95.59% | 1957.72% | 9.59% | 31.28% |
Related:IMMP Dividend History·IMMP Revenue History·IMMP Price History·IMMP P/E History·IMMP Financial Ratios·IMMP Institutional Holders
IMMP Frequently Asked Questions
Immutep Limited (IMMP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immutep Limited (IMMP) reported $8.9M in revenue for fiscal year 2025.
Immutep Limited (IMMP) grew revenue by 31.3% over the past year. This is strong growth.
Immutep Limited (IMMP) reported a net loss of $104.2M for fiscal year 2025.
Dividend & Returns
Immutep Limited (IMMP) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.
Immutep Limited (IMMP) had negative free cash flow of $97.8M in fiscal year 2025, likely due to heavy capital investments.